Thailand

Thailand's psychedelic landscape is tightly controlled and best understood as a research-limited, medically narrow environment rather than a routine access market. Ketamine is established in medical practice, but classical psychedelics remain subject to narcotics and psychotropic-substance controls, with Thai FDA materials continuing to describe psilocybin, DMT, mescaline and related compounds as restricted substances.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Thailand.

1
Thailand's psychedelics market is defined more by control and enforcement than by patient access, so most practical activity is likely to sit within research or tightly authorised medical settings.
2
Ketamine is the clearest exception in the country's medical landscape, and the available Thai FDA notices suggest it is treated as a regulated medical/narcotic substance rather than as a psychedelic access route.
3
Public Thai FDA messaging in late 2024 was still warning that psilocybin-containing mushrooms are illegal, which argues against assuming any broad patient-access opening.
4
The country's documented research signal is narrow and depression-focused, which is consistent with Blossom's linked-trial snapshot rather than a broad psychedelic clinical programme.
5
Recent Thai FDA communications point to tighter traceability and digital oversight of controlled medical substances, a sign of administrative modernisation rather than deregulation.

Research Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Thailand.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Ketamine(1)

Medical Access Snapshot

Thailand maintains a tightly regulated approach to classical psychedelics: some compounds (notably ketamine) are established in medical practice while others remain scheduled with access limited to research or prohibited outside of strict controls. A 2024 ministerial notification explicitly opened a regulatory pathway for psilocybin research/medical use, but most serotonergic psychedelics (MDMA, DMT, mescaline, 2C-X, etc.) remain controlled with no routine clinical/reimbursed access.

View trials→View stakeholders→Open access guide→

Regulatory Status

Thailand appears to permit psychedelic-related work only under strict controls, with psilocybin described by Thai FDA materials as a Category 1 psychotropic substance with no medical use and high abuse potential, while public FDA warnings in late 2024 still described magic mushrooms as illegal and punishable. A 2025 Thai FDA notice also emphasised tighter oversight and traceability for medical narcotic and psychotropic substances, suggesting continued regulatory caution rather than broad liberalisation. Any research or medical pathway for psilocybin should therefore be treated as limited, conditional and potentially changing, not routine.